Bleomycin

證據等級: L5

預測適應症: 6 個

Bleomycin: From Hodgkin’s Lymphoma to Reticulum Cell Sarcoma

One-Sentence Summary

Bleomycin is a glycopeptide antibiotic cytotoxic agent, globally established as a core component of ABVD (Hodgkin’s lymphoma) and BEP (germ cell tumour) regimens, though it currently holds no registered indications in the Philippines. The TxGNN model identifies 6 predicted new indications; the most evidence-supported is Reticulum Cell Sarcoma (now classified as Diffuse Large B-Cell Lymphoma, DLBCL), backed by 3 completed Phase 3 RCTs and 20 publications including landmark randomised trials. The remaining 5 predictions range from early investigational (adult astrocytic tumour, primary pulmonary lymphoma) to model-prediction-only, and are summarised in the multi-indication overview below.

Quick Overview

Item	Content
Original Indication	Hodgkin’s lymphoma; germ cell tumours (globally recognised; no Philippines registration)
Primary Predicted Indication	Reticulum Cell Sarcoma (Diffuse Large B-Cell Lymphoma)
TxGNN Prediction Score	99.14%
Evidence Level	L1
Philippines Market Status	✗ Not Registered
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

All Predicted Indications — Summary

Rank	Disease	TxGNN Score	Evidence Level	Clinical Trials	Literature	Decision
1	Cauda Equina Neoplasm	99.30%	L5	0	3 (all indirect)	Hold
2	Adult Astrocytic Tumour	99.28%	L3	0 (Phase I/II evidence in literature)	20	Research Question
3	Reticulum Cell Sarcoma	99.14%	L1	13 (3 completed Phase 3 RCTs)	20	Proceed with Guardrails
4	Primary Pulmonary Lymphoma	99.10%	L3	8 (indirect; Hodgkin’s lymphoma trials)	20	Research Question
5	Pulmonary Blastoma	99.04%	L4	0	2 (case reports only)	Hold
6	Well-differentiated Fetal Adenocarcinoma of the Lung	99.03%	L5	0	0	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action (MOA) data for Bleomycin is not available in this evidence pack. Based on established pharmacological knowledge, Bleomycin is a glycopeptide antibiotic that exerts antitumour activity by chelating metal ions (primarily iron) and generating reactive oxygen species, which in turn induce DNA single- and double-strand breaks. This mechanism is most effective in rapidly proliferating cells, particularly during the G₂ and M phases of the cell cycle, making it well-suited for aggressive lymphomas characterised by high proliferative indices.

Reticulum cell sarcoma is the obsolete histopathological designation for what is now classified as Diffuse Large B-Cell Lymphoma (DLBCL) — the most common aggressive non-Hodgkin’s lymphoma worldwide. Bleomycin’s DNA-damaging mechanism directly targets the rapid cell division characteristic of DLBCL. Historically, it served as a core component of regimens such as m-BACOD, ProMACE-CytaBOM, CHVmP/BV, and CHOP-Bleo. The earliest direct clinical evidence dates to 1972 (PMID 4109401), when bleomycin monotherapy was administered to 22 reticulum cell sarcoma patients in a marrow-sparing dose protocol, demonstrating objective responses. A landmark CALGB Phase III RCT (PMID 1699653, 1978–1985) directly evaluated the addition of bleomycin to CHOP in 177 patients with diffuse large cell lymphoma, and NCT00005867 enrolled 310 patients in a randomised comparison of PMitCEBO (bleomycin-containing) versus CHOP in good-risk aggressive NHL.

An important clinical caveat: modern standard-of-care for DLBCL is R-CHOP (rituximab + CHOP), which does not routinely include bleomycin. This positions bleomycin as a potential option in rituximab-ineligible patients, resource-limited settings where rituximab access is constrained, or in investigational combination strategies, rather than as a first-line replacement. Bleomycin-induced pneumonitis remains the principal safety concern and requires mandatory pulmonary function monitoring throughout treatment.

Clinical Trial Evidence — Reticulum Cell Sarcoma

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00005867	Phase 3	Completed	310	Largest trial in this set: randomised comparison of CHOP vs PMitCEBO (containing bleomycin) in good-prognosis aggressive NHL; direct comparative efficacy data for a bleomycin-containing regimen vs standard CHOP
NCT00002835	Phase 3	Completed	116	Randomised comparison of early intensification vs alternating triple therapy (ATT, bleomycin-containing) in poor-prognosis intermediate-grade / immunoblastic lymphoma; provides long-term efficacy data for bleomycin-containing regimen
NCT00002565	Phase 3	Completed	61	Randomised comparison of ATT (bleomycin-containing) vs CHOP in intermediate-grade and immunoblastic NHL (modern DLBCL classification); directly evaluates bleomycin’s added value in combination chemotherapy
NCT00057811	Phase 2	Completed	97	Rituximab + rasburicase added to bleomycin-containing induction/consolidation in newly diagnosed advanced B-cell leukaemia/lymphoma (paediatric); primarily assesses safety of combination
NCT00002571	Phase 2	Completed	52	ProMACE-CytaBOM (bleomycin-containing) + TMP/SMX + AZT + G-CSF in AIDS-related NHL; direct bleomycin use in immunocompromised subgroup; efficacy and toxicity data available
NCT00002524	Phase 2	Completed	46	Combination chemotherapy containing bleomycin in AIDS-related lymphoma; efficacy data in HIV-positive subpopulation; limits generalisability to immunocompetent patients
NCT00002657	Phase 2	Completed	20	Sequential immunosuppression reduction, interferon-α, and ProMACE-CytaBOM (bleomycin) for post-cardiac-transplant lymphoproliferation; specific transplant subgroup data
NCT00003110	Phase 2	Completed	5	72-hour continuous infusion bleomycin as salvage therapy in both AIDS-related and immunocompetent NHL; only trial directly evaluating bleomycin as a single salvage agent; very small sample
NCT00003815	Phase 3	Unknown	N/A	High-dose chemotherapy/radiotherapy and autologous BMT in high-grade aggressive NHL (Kiel classification, overlapping with reticulum cell sarcoma); bleomycin’s role within the combination regimen is not explicitly defined
NCT00983944	Phase 2	Withdrawn	0	Comparison of EPOCH-R vs R-VACOP-B (contains bleomycin) for primary mediastinal large B-cell lymphoma; withdrawn prior to any enrolment — no data generated

Literature Evidence — Reticulum Cell Sarcoma

PMID	Year	Type	Journal	Key Findings
1699653	1990	RCT	Cancer	CALGB 7851: Randomised trial directly evaluating the addition of bleomycin and/or high-dose methotrexate to CHOP in 177 diffuse large cell lymphoma and 97 other intermediate-grade NHL patients; foundational evidence for bleomycin’s role in aggressive NHL combination therapy
14962711	2004	Long-term RCT Follow-up	Eur J Cancer	Pooled analysis of 936 patients across 3 EORTC randomised trials; CHVmP/BV (with bleomycin + vincristine) vs CHVmP and ProMACE-MOPP in advanced aggressive NHL; median follow-up 8.7 years with long-term efficacy and toxicity data
4109401	1972	Early Clinical Trial	BMJ	Earliest direct evidence: Bleomycin monotherapy in 22 reticulum cell sarcoma patients (+ 54 Hodgkin’s, 17 lymphosarcoma); marrow-sparing up to 800 mg total dose; response rates documented in reticulum cell sarcoma specifically
65728	1977	Clinical Trial	Med Pediatr Oncol	Randomised comparison of CVP vs ABP (adriamycin + bleomycin + prednisone) in stage IV NHL; 30 evaluable ABP patients; comparable CR rates (50%) with numerically longer CR duration in bleomycin-containing arm (20.5 vs 10.5 months)
7680764	1993	RCT	N Engl J Med	SWOG landmark trial: CHOP vs m-BACOD, ProMACE-CytaBOM, and MACOP-B in advanced NHL; established CHOP’s equivalent efficacy to third-generation bleomycin-containing regimens with lower toxic death rate; key context for modern bleomycin positioning
6187214	1983	Case Report (Fatal Toxicity)	Am J Med	Fatal fulminant hyperpyrexia in a lymphoma patient with prior bleomycin exposure without prior reaction; underscores the unpredictability of febrile reactions and the need for vigilance beyond the first administration
37294956	2023	Review	Hematol Oncol	Contemporary management of lymphoma in pregnancy; confirms ABVD (containing bleomycin) is considered safe after the 13th week of pregnancy; provides current risk-benefit context
6205233	1984	Review	Med Clin North Am	Comprehensive review of NHL classification, natural history, staging, and treatment; covers bleomycin-containing combination regimens and their rationale in the era of histological reclassification from “reticulum cell sarcoma” to DLBCL
15934513	2005	Review	Oncology	GELA 20-year experience with Phase II/III studies in aggressive lymphoma/DLBCL; discusses limitations of CHOP and the role of intensified regimens including bleomycin-containing combinations
12967352	2003	Review	Clin Evid	Evidence-based systematic review of NHL management; evaluates the evidence base for bleomycin-containing combination regimens across histological subtypes

Philippines Market Information

Bleomycin is currently not registered in the Philippines. No marketing authorisations are on record in the Philippines FDA database.

Item	Detail
Market Status	Not Registered (未上市)
Total Authorisations	0
Registration Pathway	A new Drug Registration Application to the Philippines FDA would be required prior to any clinical deployment
International Availability	Bleomycin is available in other markets under names such as Blenoxane® (Bristol-Myers Squibb) and various generics; it is included in the WHO Model List of Essential Medicines

Cytotoxicity

Bleomycin is an antineoplastic glycopeptide antibiotic. This section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Glycopeptide antibiotic / DNA strand-break inducer)
Myelosuppression Risk	Low — Bleomycin is notably marrow-sparing, which is a key pharmacological advantage in combination regimens such as ABVD; routine CBC monitoring is still recommended
Emetogenicity Classification	Low
Primary Organ Toxicity	Pulmonary: Bleomycin-induced pneumonitis and pulmonary fibrosis are dose-dependent and cumulative; risk threshold typically around 300–360 units lifetime cumulative dose; risk substantially increased by age > 60, renal impairment, concurrent G-CSF use, and prior chest irradiation
Monitoring Items	Pulmonary function tests (DLCO) before initiation and before each cycle or at regular intervals; renal function (bleomycin is primarily renally eliminated — dose reduction required in renal impairment); cumulative dose tracking across all treatment cycles; temperature monitoring post-infusion (acute hyperpyrexia risk)
Handling Protection	Must follow cytotoxic drug handling regulations (PPE, closed-system drug-transfer devices, designated preparation areas)

Safety Considerations

Formal safety data (package insert warnings and contraindications) were not available in this evidence pack. Based on toxicity data identified in the clinical literature reviewed:

Pulmonary toxicity: Bleomycin-induced pneumonitis and pulmonary fibrosis are the most clinically significant toxicities; risk is amplified by increasing age (PMID 31668826), concurrent granulocyte colony-stimulating factor use, prior chest radiation, and cumulative dose exceeding 300–360 units (PMID 27742539)
Hyperpyrexia: Acute and potentially fatal febrile reactions have been reported, including in patients who previously tolerated bleomycin without incident (PMID 6187214); a test dose is recommended before initiating a full course
Drug Interactions: No DDI data were identified in this review

Please refer to the approved package insert for comprehensive safety information including contraindications and full warning statements.

Conclusion and Next Steps

Decision: Proceed with Guardrails (primary indication: Reticulum Cell Sarcoma / DLBCL)

Rationale: The evidence supporting bleomycin in reticulum cell sarcoma (DLBCL) reaches Evidence Level 1 — anchored by at least three completed Phase 3 RCTs and a landmark CALGB randomised trial (PMID 1699653) directly evaluating bleomycin’s contribution to CHOP in diffuse large cell lymphoma. However, the modern DLBCL standard-of-care has evolved to R-CHOP (rituximab + CHOP), where bleomycin is no longer routinely included; this means the actionable niche lies specifically in rituximab-ineligible patients, resource-constrained settings, or novel combination strategies rather than as a blanket first-line addition.

To proceed, the following is needed:

MOA data: Retrieve complete mechanism of action details from DrugBank API (Data Gap DG002 — currently flagged as High severity)
Package insert review: Download and parse the approved product monograph for formal warnings, contraindications, and dosing guidance (Data Gap DG001 — currently flagged as Blocking)
Current treatment context analysis: Formally assess whether bleomycin-containing regimens offer a meaningful advantage over R-CHOP in the specific target patient population (e.g., rituximab-ineligible, CD20-negative DLBCL)
Pulmonary toxicity risk management protocol: Establish a pre-treatment DLCO baseline monitoring protocol and define cumulative dose limits and stopping rules before any clinical deployment
Philippines registration pathway: Initiate a Drug Registration Application with the Philippines FDA if clinical deployment is planned — no current authorisation exists and this is a prerequisite for lawful use

Summary of decisions for remaining predicted indications:

| Indication | Decision | Key Reason | |———–|———-|————| | Adult Astrocytic Tumour | Research Question (L3) | Phase I intratumoral CED trial data exists (PMID 12416544); blood-brain barrier bypass remains a key challenge; no Phase 2/3 data | | Primary Pulmonary Lymphoma | Research Question (L3) | Indirect evidence from Hodgkin’s lymphoma ABVD trials only; elevated bleomycin pulmonary toxicity risk is of particular concern in patients with primary lung involvement | | Cauda Equina Neoplasm | Hold (L5) | No clinical trials; 3 indirect literature references only; TxGNN high score likely reflects topology-based propagation in the knowledge graph rather than a true mechanistic link | | Pulmonary Blastoma | Hold (L4) | Only 2 case reports; bleomycin use attributable to germ cell differentiation component (BEP regimen), not to pulmonary blastoma itself | | Well-differentiated Fetal Adenocarcinoma of the Lung | Hold (L5) | Zero clinical trials and zero literature; no mechanistic basis identified; complete absence of evidence |

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.